Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Plavix Will Slow U.S. Pharmaceutical Sales Growth In 2006 – IMS

Executive Summary

The launch of generic Plavix (clopidogrel) could reduce overall pharmaceutical sales growth for 2006 by nearly one percent, IMS Health VP-Industry Relations Doug Long suggested
Advertisement

Related Content

Teva Touts CNS-Focused Branded Pipeline, Expects 15 Filings By 2015
Teva Touts CNS-Focused Branded Pipeline, Expects 15 Filings By 2015
Plavix Generic Blocked By Court, But Damage Lingers For Bristol And Sanofi
Plavix Generic Blocked By Court, But Damage Lingers For Bristol And Sanofi
Pharmaceutical 2005 Sales Growth Due To Price Increases, Not Volume
Advertisement
UsernamePublicRestriction

Register

PS047560

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel